Oncternal Therapeutics, Inc. - ONCT
About Gravity Analytica
Recent News
- 03.07.2025 - Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
- 03.07.2025 - Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
- 10.22.2024 - Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
- 10.22.2024 - Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
- 10.22.2024 - Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
- 09.12.2024 - Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
- 09.12.2024 - Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
- 09.12.2024 - Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
- 09.10.2024 - Phase 1-2 TK216 Ewing sarcoma (Meyers et al. JCO 2024)
- 09.10.2024 - Phase 1b Zilovertamab paclitaxel MBC (Shatsky et al. BrCaRes 2024)